CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance

Gao, Tian; Han, Yong; Yu, Ling; Ao, Sheng; Li, Ziyu; Ji, Jiafu
March 2014
PLoS ONE;Mar2014, Vol. 9 Issue 3, p1
Academic Journal
Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNA2 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNA2 was closely associated with tamoxifen resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, though CCNA2-Drug interaction network, we demonstrated the interactions between CCNA2 and several available cancer drugs. Overall, we suggest that CCNA2 is a biomarker for the prognosis of ER+ breast cancer and monitoring of tamoxifen efficacy. It's also a promising target for developing new strategies to prevent or even reverse tamoxifen resistance. Moreover, CCNA2 expression may help monitoring tamoxifen efficacy and directing personalized therapies. Nevertheless, in vivo and in vitro experiments and multi-center randomized controlled clinical trials are still needed before its application in clinical settings.


Related Articles

  • Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.  // World Journal of Surgical Oncology;2011, Vol. 9 Issue 1, p131 

    The article presents a research conducted on examining the frequency and clinical significance of ER/PgR, HER2, and Ki-67 biological markers for predicting prognosis and making effective treatment decisions in breast cancer. It investigates the changes in markers and their correlations with...

  • A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen. Leeuw, Renée de; Neefjes, Jacques; Michalides, Rob // International Journal of Breast Cancer;2011, p1 

    About two thirds of all human breast cancer cases are estrogen receptor positive. The drug of first choice for these patients is tamoxifen. However, about half of the recurrences after removal of the primary tumor are or become resistant to this drug. While many mechanisms have been identified...

  • Molecular functions and significance of the MTA family in hormone-independent cancer. Ning, Zhifeng; Gan, Jinfeng; Chen, Chaoying; Zhang, Dianzheng; Zhang, Hao // Cancer & Metastasis Reviews;Dec2014, Vol. 33 Issue 4, p901 

    The members of the metastasis-associated protein (MTA) family play pivotal roles in both physiological and pathophysiological processes, especially in cancer development and metastasis, and their role as master regulators has come to light. Due to the fact that they were first identified as...

  • Breast Cancer Chemoprevention: The Saga of Underuse Continues. Wickerham, D. Lawrence; Vogel, Victor G. // JNCI: Journal of the National Cancer Institute;Dec2014, Vol. 107 Issue 1, p1 

    The article discusses research on the risk-benefit profiles of women using tamoxifen for chemoprevention. Topics discussed include reasons for the high adherence rates to selective estrogen receptor modulator (SERM) therapy, actions to be considered to increase the number of women offered the...

  • Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Cancello, G.; Maisonneuve, P.; Rotmensz, N.; Viale, G.; Mastropasqua, M. G.; Pruneri, G.; Montagna, E.; Iorfida, M.; Mazza, M.; Balduzzi, A.; Veronesi, P.; Luini, A.; Intra, M.; Goldhirsch, A.; Colleoni, M. // Annals of Oncology;Mar2013, Vol. 24 Issue 3, p661 

    Background The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis. Patients and methods We explored patterns of recurrence in...

  • Estrogen receptors in human disease. Cadenas, C.; Bolt, H. // Archives of Toxicology;Oct2012, Vol. 86 Issue 10, p1489 

    The authors reflect on the role of estrogen receptors in human disease. They state that the loss and overexpression of estrogen receptors may contribute to the development of disease. They mention that estrogen receptors play significant role in prognosis and chemoresistance beside cancer cell...

  • Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J B Arnes // Journal of Clinical Pathology;Feb2009, Vol. 62 Issue 2, p139 

    AIMS: BRCA1-related breast cancer is associated with a basal-like phenotype, and is frequently oestrogen receptor (ER) and HER2 negative. The expression of epidermal growth factor receptor (EGFR) has been considered to be one component of the basal-like phenotype, but no standard criteria exist....

  • Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Vesuna, F; Lisok, A; Kimble, B; Domek, J; Kato, Y; van der Groep, P; Artemov, D; Kowalski, J; Carraway, H; van Diest, P; Raman, V // Oncogene;7/5/2012, Vol. 31 Issue 27, p3223 

    The role of estrogen receptor-α (ER) in breast cancer development, and as a primary clinical marker for breast cancer prognosis, has been well documented. In this study, we identified the oncogenic protein, TWIST1 (Twist), which is overexpressed in high-grade breast cancers, as a potential...

  • Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)--first results from PathIES. Speirs, V.; Viale, G.; Mousa, K.; Palmieri, C.; Reed, S. N.; Nicholas, H.; Cheang, M.; Jassem, J.; Lønning, P. E.; Kalaitzaki, E.; van de Velde, C. J. H.; Rasmussen, B. B.; Verhoeven, D. M.; Shaaban, A. M.; Bartlett, J. M. S.; Bliss, J. M.; Coombes, R. C. // Annals of Oncology;Sep2015, Vol. 26 Issue 9, p1890 

    Background: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. PathIES aimed to assess the potential prognostic and predictive value of ERβ1 and ERβ2 expression in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics